奥曲肽联合普萘洛尔治疗肝细胞癌并发门脉高压症患者门静脉血流动力学的变化

doi:10.3969/j.issn.1672-5069.2016.04.028

Abstract

Jiang Jihao, Tan Dingwu, Liu Xing. Effect of octreotide combined with propranolol on venous blood flow and portal hemodynamics in treatment of patients with primary liver cancer complicated by portal hypertension[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 486-487.

References

[1] Lake-Bakaar G,Ahmed M,Evenson A,et al. Management of hepatocellular carcinoma in cirrhotic patients with portal hypertension:Relevance of Hagen-Poiseuille's law. Liver Cancer, 2014,3（3-4）:428-438.
[2] 谭友文,於学军,殷玉梅,等. 肝硬化门静脉高压症门脉血流动力学检测及其临床意义.中华超声影像学杂志,2001,10（3）：151-153.
[3] Dumont F,Goudard Y,Caramella C,et al. Therapeutic strategies for advanced pancreatic neuroendocrine tumors with segmental portal hypertension. World J Surg,2015,39（8）:1974-1980.
[4] 全国癌症防治办公室,中国抗癌协会.中国常见恶性肿瘤诊治规范. 北京：北京医科大学,中国协和医科大学联合出版社,1990：22-30.
[5] 季伟,王炜,吕金捍,等. 影响乙型肝炎病毒相关原发性肝癌患者生存因素分析. 实用肝脏病杂志,2015,18（6）：638-642.
[6] Su Z, Niu J,Xiao Y,et al. Effect of octreotide-polyethylene glycol（100） monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm,2011,8（5）:1641-1651.
[7] Fischbach J,Gut P,Matysiak-Grze M,et al. Combined octreotide and peptide receptor radionuclide therapy（90）Y-DOTA-TATE） in case of malignant insulinoma. Neuro Endocrinol Lett, 2012,33（3）:273-278.
[8] 张郁峰,易永祥,陈昌浩,等. 肝癌并发中重度门静脉高压症外科治疗决策的风险因素分析.中国普通外科杂志,2012,21（7）：787-790.
[9] Kattan J,Chemaly A,Chemaly M,et al. Inflammatory breastcancer with refractory diarrhea:a case report. J Med Liban,2011,59（3）:165-167.
[10] 杨平华,屈淑平,程张军,等.肝癌伴门静脉高压症的肝切除术.肝脏,2012,17（9）：626-629.
[11] Miyazaki K,Orton MR,Davidson RL,et al. Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology,2012,263（1）:139-148.
[12] 王吉耀. 肝硬化门脉高压食管胃静脉曲张出血的防治.实用肝脏病杂志,2013,16（3）：195-197.
[13] Hu Q,Takeishi K,Yamashita Y,et al. Splenectomy followed by hepatectomy for hepatocellular carcinoma with hypersplenism and portal hypertension caused by macroglobulinemia. Anticancer Res,2015,35（7）:4077-4081.
[14] Spetz J,Dalmo J,Nilsson O,et al. Specific binding and uptake of 131 I-MIBG and 111 In-octreotide in metastatic paraganglioma tools for choice of radionuclide therapy. Horm Metab Res,2012,44（5）:400-404.
[15] Xia Q,Liu J,Wu C,et al. Prognostic significance of FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis.Cancer Imaging,2015,15（1）:19.

Effect of octreotide combined with propranolol on venous blood flow and portal hemodynamics in treatment of patients with primary liver cancer complicated by portal hypertension

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[6]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[7]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[8]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[9]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[10]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[13]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[14]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[15]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.